View clinical trials related to Head and Neck Neoplasms.Filter by:
IntraGel's polymer-based Cisplatin loaded Gel (TumoCure) is a single injectable compound, aimed at localized chemotherapy treatment. The treatment is offered to patients who currently have no other available treatment options, either due to inefficacy, intolerability or inapplicability of standard treatment
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
The aim of this study is to test the potential of IMRT in sparing of Dysphagia/ Aspiration risk structures and contra lateral submandibular gland in HNSCC of the oropharynx, larynx and the hypopharynx after radical concurrent chemoradiotherapy or radiotherapy. Primary objective of the SWOAR trial is to determine whether sparing the dysphagia aspiration-related structures (DARS) by IMRT (SWOAR IMRT) improves swallowing function compared to Standar IMRT (S- IMRT) in advanced HNSCC. The impact of sparing the DARS with SWOAR-IMRT on late swallowing function will be evaluated the MDADI. Difference in the mean composite score of MDADI, a patient-reported outcome, at 6 months post radiotherapy is the primary outcome of the trial. Secondary Objectives include longitudinal assessment of aspiration prevention as evaluated by FEES by the 8 point penetration-aspiration score. Swallowing function, will be assessed by using the MDADI at baseline, at completion of CRT/RT, 3, 6, 12, and 24 months. Assessment of acute and late toxicity assessed at baseline, weekly during radiotherapy and then at 3, 6, 12, and 24 months post treatment as per RTOG and LENT SOMA score, respectively. Treatment outcomes will be assessed in terms of loco-regional tumor recurrence and overall survival, assessed at follow-up visits 3, 6, 12, and 24 months post treatment and then annually until 5 years post treatment.
Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.
A Phase 1/2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
This randomized clinical trial aims to compare therapist-administered (usual care, clinic-based) CDT and self-administered (home-based, hybrid model) CDT on changes in the severity of lymphedema, symptom burden, functional status, and healthcare utilization in HNC survivors with lymphedema.
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
This phase II trial studies how well pembrolizumab alone or in combination with ipatasertib works in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or has spread to other places in the body (metastatic). Ipatasertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ipatasertib in combination with pembrolizumab may kill more tumor cells in patients with recurrent/metastatic squamous cell cancer of the head and neck.
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach chemotherapy given together with radiation therapy ("chemo-radiation") that can be safely and tolerably taken by patients with stage III-IVB head and neck cancer. AKT inhibitors such as, ipatasertib work to stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib with chemoradiation may help cure head and neck cancer.
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.